Metoprolol and Hypoglycemia Risk

Mechanism and Risk

Beta-blockers, including metoprolol, can alter counter-regulatory responses to hypoglycemia with decreased tremor and palpitations but increased sweating in diabetic patients, according to the European Society of Cardiology 1, 2, 3
Prolonged hypoglycemia has been described with non-cardio-selective beta-blockade, but is less common with beta-1-selective agents like metoprolol, as reported by the European Heart Journal 1, 2, 3

Elderly diabetic patients on insulin experienced an increased risk of serious hypoglycemia with non-selective beta-blockade, but not with beta-1-selective drugs like metoprolol, with a relative risk of 0.86 and 95% CI 0.36–1.33, as found by the European Heart Journal 1, 2, 3

Patients with diabetes who require beta-blockers should preferentially receive cardioselective agents like metoprolol rather than non-selective beta-blockers, as recommended by the European Society of Cardiology 1, 3
In patients with heart failure and diabetes, carvedilol might have more favorable effects on glycemic control than metoprolol succinate and bisoprolol, according to the American Heart Association 4

In children receiving propranolol, administering the medication with feeds and holding doses during times of diminished oral intake or vomiting is recommended to reduce hypoglycemia risk, as suggested by the American Academy of Pediatrics 5
This principle can be applied to adult patients taking metoprolol who are at high risk for hypoglycemia, with a strength of evidence based on expert opinion 5

Beta-blockers should be used with great caution in individuals with conditions predisposing to hypoglycemia because of their potential to mask symptoms, according to Genetics in Medicine 6

For patients with heart failure and diabetes, careful monitoring of blood glucose is essential when using any beta-blocker, but the risk is lower with cardioselective agents, as stated by the American College of Cardiology 7

The American Heart Association notes that in patients with heart failure and diabetes, carvedilol might have more favorable effects on glycemic control than metoprolol succinate 8
Carvedilol and nebivolol (vasodilating beta-blockers) affect insulin sensitivity less than metoprolol 9
Nebivolol has been shown not to worsen glucose tolerance compared to placebo, even when added to hydrochlorothiazide 9
In the metabolic syndrome, beta-blockers with vasodilating properties (carvedilol, nebivolol) are preferred over traditional beta-blockers like metoprolol due to their more favorable metabolic profile 10